63762-72-1

Usage

Uses

Used in Pharmaceutical Industry:
1H-Indole, 6-chloro-5-methoxyis used as a building block for the synthesis of various pharmaceutical compounds. Its unique structural conformation allows for further modifications to create new drugs with potential therapeutic applications.
Used in Materials Science:
1H-Indole, 6-chloro-5-methoxyis used as a component in the development of new materials with specific properties. The versatility of its structure enables its incorporation into a wide range of materials, such as polymers, coatings, and adhesives, to enhance their performance and functionality.

InChI:InChI=1/C9H8ClNO/c1-12-9-4-6-2-3-11-8(6)5-7(9)10/h2-5,11H,1H3

Upstream product

• 63762-71-0 2-chloro-5-<(β-dimethylamino)-vinyl>-4-nitroanisole 
• 1203844-49-8 C₁₃H₁₅ClN₂O₃ 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 118664-99-6 1-chloro-2-fluoro-4-methyl-5-nitrobenzene 
• 62492-45-9 2-nitro-4-chloro-5-methoxymethylbenzene 
• 40130-97-0 2-chloro-5-methyl-4-nitro-phenol 
• 615-74-7 2-chloro-5-methylphenol 
• 99474-19-8 2-(4-chloro-5-methoxy-2-nitrophenyl)-1-dimethylamino ethylene 

Downstream Products

• 63762-74-3 N-[2-(6-chloro-5-methoxy-indol-3-yl)-ethyl]-acetamide 
• 164084-11-1 2-(1-Benzyl-2-bromo-6-chloro-5-methoxy-1H-indol-3-yl)-acetamide 
• 164083-10-7 (1-Benzyl-2-bromo-6-chloro-5-methoxy-1H-indol-3-yl)-acetic acid methyl ester 
• 164083-09-4 (1-Benzyl-6-chloro-5-methoxy-1H-indol-3-yl)-acetic acid methyl ester 
• 63762-73-2 (6-chloro-5-methoxy-indol-3-yl)-acetonitrile 

Relevant academic research and scientific papers

KINASE INHIBITORS AND METHODS OF USE

The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3βinhibitors that suppress proliferation and survival of pancreatic cancer cells

Recent studies have demonstrated that glycogen synthase kinase 3β (GSK-3β) is overexpressed in human colon and pancreatic carcinomas, contributing to cancer cell proliferation and survival. Here, we report the design, synthesis, and biological evaluation of benzofuran-3-yl-(indol-3-yl) maleimides, potent GSK-3β inhibitors. Some of these compounds show picomolar inhibitory activity toward GSK-3β and an enhanced selectivity against cyclin-dependent kinase 2 (CDK-2). Selected GSK-3β inhibitors were tested in the pancreatic cancer cell lines MiaPaCa-2, BXPC-3, and HupT3. We determined that some of these compounds, namely compounds 5, 6, 11, 20, and 26, demonstrate antiproliferative activity against some or all of the pancreatic cancer cells at low micromolar to nanomolar concentrations. We found that the treatment of pancreatic cancer cells with GSK-3β inhibitors 5 and 26 resulted in suppression of GSK-3β activity and a distinct decrease of the X-linked inhibitor of apoptosis (XIAP) expression, leading to significant apoptosis. The present data suggest a possible role for GSK-3β inhibitors in cancer therapy, in addition to their more prominent applications in CNS disorders.

Synthesis and evaluation of the antiovulatory activity of a variety of melatonin analogues

A series of melatonin analogues was synthesized and examined for ovulation-blocking activity. Deviation from the 5-methoxy group or substitution of the 1 position prevented activity. Activity was not particularly sensitive to minor variations in the N-acyl group nor was it significantly altered by methylation of position 2 or the α-methylene; however, a pronounced enhancement resulted from halogenation of the 6 position.